Advertisement

Advertisement
Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Atezolizumab Plus Nab-paclitaxel

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Atezolizumab Plus Nab-paclitaxel

Neoadjuvant Talazoparib for Operable BRCA-Mutated Breast Cancer

In a study reported in the Journal of Clinical Oncology, Litton et al found that 6 months of neoadjuvant talazoparib therapy resulted in a high rate of pathologic complete response in patients with stage I–III breast cancer with germline pathogenic BRCA mutations.

Pregnancy Appears Safe After Treatment for Breast Cancer in Patients With BRCA Mutations

Pregnancy Appears Safe After Treatment for Breast Cancer in Patients With <em>BRCA</em> Mutations

Pregnancy after breast cancer appears to be safe in patients with germline BRCA mutations—and particularly among those with BRCA1 mutations...

Menopausal Hormone Therapy Use and Risk of Breast Cancer

In a study reported in The Lancet, the Collaborative Group on Hormonal Factors in Breast Cancer found that the use of menopausal hormone therapy is associated with an increased risk of breast cancer, with risk increasing as duration of use increases, in both current and past users.

USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk

In a statement published in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended that clinicians offer to prescribe risk-reducing medications to women who are at an increased risk of breast cancer and at low risk of adverse events related to medications. However, the Task Force recommended against the routine use of risk-reducing medications in women who are not at an increased risk of breast cancer.

T-DM1 Plus Neratinib in Metastatic HER2-Positive Breast Cancer

T-DM1 Plus Neratinib in Metastatic HER2-Positive Breast Cancer

In the phase Ib NSABP Foundation Trial FB-10 reported in the Journal of Clinical Oncology, Abraham et al found evidence of activity of the combination of ado-trastuzumab emtansine (T-DM1) plus neratinib in metastatic HER2-positive breast cancer and identified the dose of the combination for phase II testing.

Advertisement


Advertisement